A new study published in Nature Communications tested a simple nasal swab to find early changes linked to Alzheimer’s. Detecting the disease early matters because new treatments may work best at that stage.
Researchers used a gentle swab placed high inside the nose. After a numbing spray, a clinician guided a tiny brush to the upper nose where smell nerve cells live. Scientists then measured which genes were active in the collected cells.
The team compared samples from 22 participants and looked at thousands of genes across many cells. A combined gene score separated early and clinical Alzheimer’s from healthy people about 81% of the time. The researchers plan larger studies next.
Difficult words
- study — short research report about a topic
- nasal swab — soft tool taken from inside the nose
- clinician — trained health worker who gives medical care
- gene — parts of cells that control traits and activitygenes
- participant — people who take part in a studyparticipants
- separate — show a clear difference between two groupsseparated
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you agree to a nasal swab test to check for early disease? Why or why not?
- How would you feel if a clinician used a tiny brush inside your nose for a test?
Related articles
Which childhood food allergies are outgrown?
Many children outgrow milk and egg allergies, while peanut, tree nut, sesame and shellfish allergies often persist. Factors such as IgE levels, allergy severity and genetics affect whether a child becomes tolerant and which treatments help.
Demand for clean-energy minerals harms poor regions
A UN report warns that rising global demand for minerals for clean energy is causing environmental damage, water loss and health harms in poorer mining regions, while richer countries gain most benefits. The report urges reforms to protect water and people.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.